BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Flexion Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference


1/4/2013 7:10:10 AM

WOBURN, Mass., Jan. 4, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc., a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders, today announced that the company will present at the 31st Annual J.P. Morgan Healthcare Conference.

Michael Clayman, M.D., Flexion's chief executive officer, is scheduled to present a corporate overview at 11:30 a.m. PST on Wednesday, January 9, 2013 in the Elizabethan C/D Ballroom of the Westin St. Francis Hotel. The conference will be held from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco, CA.

About Flexion Therapeutics
Flexion is a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety, we are merging novel pharmacology with local, sustained delivery of drug to the site of disease an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid, is currently being evaluated in a Phase 2b dose-ranging study with data expected in the middle of 2013. FX007, an intra-articular sustained release TrkA inhibitor, is being developed to safely address the intractable pain associated with end-stage osteoarthritis.

For more information please visit www.flexiontherapeutics.com.

Corporate Contact
Lisa Davidson, MBA
Vice President, Finance and Administration
T: 781-897-9965
ldavidson@flexiontherapeutics.com

Media Contacts
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners
T: 212-845-4251
T: 212-845-4272
tony.russo@russopartnersllc.com
matt.middleman@russopartnersllc.com

Investor Contact
John Woolford
Westwicke Partners
T: 443-213-0506
john.woolford@westwicke.com


SOURCE Flexion Therapeutics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->